Showing results (141-150 of 163) with videos related to
Sort By:
Pageof 17
Dermatology and Therapy|December 9, 2022
Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European InitiativeJan Koren, Jo L W Lambert, Simon F Thomsen, et al.Diagnostic Microbiology and Infectious Disease|October 23, 2021
Clinical evaluation of the Procleix SARS-CoV-2 assay, a sensitive, high-throughput test that runs on an automated systemSilvia Sauleda, Lourdes Palacios, Vanessa Brès, et al.Blood Transfusion = Trasfusione Del Sangue|November 16, 2020
Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patientsEduardo Muñiz-Diaz, Jaume Llopis, Rafael Parra, et al.Journal of the American Academy of Dermatology|August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.Archives of Dermatological Research|March 18, 2019
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective studyIrina Gasslitter, Natalia Kirsten, Matthias Augustin, et al.Acta Dermato-Venereologica|November 20, 2019
Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease RiskC Elise Kleyn, Peter S Talbot, Nehal N Mehta, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 27, 2010
Juvenile psoriasis and its clinical management: a European expert group consensusMona Ståhle, Nilgun Atakan, Wolf-Henning Boehncke, et al.Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.Frontiers in Public Health|February 13, 2023
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in SpainPaulina Maravilla-Herrera, María Merino, Santiago Alfonso Zamora, et al.Pageof 17